- Thermo Fisher’s adjusted earnings per share (EPS) for the third quarter came in at $5.28, slightly above the expected $5.25 but below last year’s $5.69.
- Revenue for the third quarter was $10.60 billion, showing a minor increase of 0.2% year-over-year, but slightly missing the estimated $10.65 billion.
- Life sciences revenue dropped by 1.9% year-over-year to $2.39 billion, falling short of the $2.46 billion expectation.
- The analytical instruments segment saw a 3.1% rise in revenue, reaching $1.81 billion, aligning perfectly with estimates.
- Specialty diagnostics revenue increased by 4.2% year-over-year to $1.13 billion, surpassing the expected $1.11 billion.
- Lab products and services brought in $5.74 billion, a marginal 0.2% increase year-over-year, meeting the estimate of $5.73 billion.
- There was a 0% impact from foreign currency on sales, compared to a 1% impact the previous year, better than the estimated 0.13% impact.
- Adjusted operating income declined by 7.7% year-over-year to $2.36 billion, just shy of the $2.37 billion estimate.
- The adjusted operating margin was 22.3%, down from last year’s 24.2%, and slightly below the 22.5% estimate.
- Eliminations revenue amounted to -$467 million, a 10% decrease year-over-year, and close to the projected -$459.3 million.
- Thermo Fisher has raised its full-year adjusted EPS guidance to a range of $21.35 to $22.07, narrowing the lower end from the previous guidance.
- Company leadership expressed satisfaction with the strong financial results and sequential improvement in growth.
- Analyst recommendations for Thermo Fisher include 23 buys and 6 holds, with no sell recommendations.
“`
Thermo Fisher Scientific Inc on Smartkarma
Thermo Fisher Scientific Inc. has been under the spotlight of analyst coverage on Smartkarma, the independent investment research network. One such report by Baptista Research delved into the company’s market positioning and competitive differentiation in a recent study titled “Thermo Fisher Scientific Inc.: What Is The Framework Behind Their Market Positioning and Competitive Differentiation? – Major Drivers.” The analysis of Thermo Fisher’s second-quarter 2024 financial results showcased a mixed performance, highlighting strengths like a solid revenue posting of $10.54 billion and an adjusted operating income of $2.35 billion, leading to an improved adjusted operating margin of 22.3%.
Another report by Baptista Research on Smartkarma explored Thermo Fisher’s long-term growth strategy towards market share expansion. The article, “Thermo Fisher Scientific: What Is Their Long-Term Growth Strategy Towards Market Share Expansion? – Major Drivers,” commended the company’s strong start to the year with first-quarter revenue reaching $10.34 billion and an increase in adjusted EPS to $5.11 per share. The impressive financial performance was attributed to operational discipline, commercial execution, and an effective growth strategy, culminating in raised guidance and setting the stage for continued strong performance in 2024.
A look at Thermo Fisher Scientific Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Thermo Fisher Scientific Inc, a company known for manufacturing scientific instruments, consumables, and chemicals, has garnered a positive outlook in the long term based on the Smartkarma Smart Scores. With a solid score in momentum and growth, the company is poised for continued success in the future. The momentum score of 4 indicates a strong upward trend, while the growth score of 3 suggests promising potential for expansion. This positions Thermo Fisher Scientific Inc well for sustained advancement and development within the industry.
Additionally, the company demonstrates resilience with a score of 3, indicating its ability to weather challenges and maintain stability. Although the value and dividend scores are more moderate at 2, the overall outlook for Thermo Fisher Scientific Inc remains optimistic, given its strengths in momentum, growth, and resilience. Investors may find potential in this company for long-term growth and stability in the scientific instruments and consumables sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
